Schedule III and Cannabis Taxes: How Rescheduling Could Reshape 280E Planning

Cannabis rescheduling has been one of the most closely watched federal issues in the industry for years. For operators, investors, lenders, and advisors, the conversation often starts with policy. But for cannabis businesses, the more immediate question is financial.

What happens to taxes, cash flow, deductions, reporting, and long-term planning if cannabis moves from Schedule I to Schedule III?

The answer is promising, but still complicated.

The federal government has taken meaningful steps toward rescheduling certain medical cannabis activity. The U.S. Department of the Treasury reported that the Department of Justice’s final order places FDA-approved cannabis products and cannabis subject to a qualifying state medical cannabis license into Schedule III. At the same time, unlicensed cannabis crops, bulk cannabis, and certain other cannabis products remain in Schedule I.For cannabis businesses, that distinction is important. Rescheduling may create new financial opportunities, especially around Section 280E, but it does not mean full federal legalization

What Cannabis Rescheduling Means for the Industry in 2026

Cannabis has historically been classified as a Schedule I controlled substance under federal law. Schedule I substances are treated as having no currently accepted medical use and a high potential for abuse. Schedule III substances are still controlled, but they are treated differently under federal law because they have accepted medical use and a lower abuse potential than Schedule I or II substances.

The shift to Schedule III could create several broad changes for the cannabis industry. It may improve medical cannabis research, strengthen credibility with some financial institutions, support more traditional tax treatment for qualifying businesses, and create a clearer federal framework for certain medical cannabis activity.

However, Schedule III is still federally regulated. Businesses should expect new layers of compliance, including registration, recordkeeping, security protocols, and federal oversight.

As Cannabis Business Times reported, congressional researchers have said medical cannabis businesses will need to register with the DEA to be Schedule III compliant. The same article noted that the DOJ’s order does not immediately bring state-licensed operators into full compliance with federal law.

That creates a more complicated reality for cannabis operators. Rescheduling may reduce some federal tax pressure, but it also introduces new compliance questions that businesses will need to work through carefully.

Why Section 280E Is Central to Cannabis Rescheduling

For many cannabis businesses, Section 280E is the biggest financial issue tied to rescheduling.

Section 280E of the Internal Revenue Code prevents businesses from taking deductions or credits if they are trafficking in Schedule I or Schedule II controlled substances. The statute, outlined by Cornell Law School’s Legal Information Institute, applies specifically to trade or business activity involving controlled substances prohibited by federal law or state law.

Because cannabis has been treated as Schedule I, state-legal cannabis businesses have faced a much heavier tax burden than most other companies. They can generally account for cost of goods sold (COGS), but they cannot deduct many ordinary business expenses. That includes items such as payroll, rent, marketing, insurance, professional services, administrative costs, and other operating expenses that most companies use to calculate taxable income.

The result is that many cannabis businesses pay federal income tax on an amount that is much higher than their actual operating profit.

If qualifying cannabis activity moves to Schedule III, 280E should no longer apply to that qualifying activity because 280E is tied to Schedule I and Schedule II substances. The U.S. Department of the Treasury has said rescheduling is expected to have “significant positive tax consequences” for medical cannabis businesses because it generally removes 280E as a barrier for businesses that no longer traffic in Schedule I or II controlled substances.

For operators, this could be one of the most meaningful financial changes the cannabis industry has seen.

How 280E Relief Could Affect Cannabis Cash Flow

If 280E no longer applies to qualifying medical cannabis activity, operators may be able to deduct ordinary and necessary business expenses in a more traditional way. That could improve after-tax cash flow, reduce effective tax rates, and give businesses more flexibility to reinvest in operations.

For cannabis operators, that could affect:

• Operating budgets
• Hiring and payroll planning
• Debt service
• Expansion decisions
• Equipment purchases
• Inventory strategy
• Investor reporting
• Business valuations
• Potential M&A activity

For example, a business that has been unable to deduct significant payroll, rent, marketing, or professional fees may see a major difference in taxable income if those deductions become available. That could free up capital for reinvestment, debt reduction, or operational improvements.

But operators should avoid assuming that tax relief will solve every financial challenge. Rescheduling may improve the tax picture, but businesses will still need to manage pricing pressure, margin compression, wholesale volatility, inventory controls, labor costs, debt obligations, and compliance risk.

A lower tax burden is helpful. It is not a substitute for strong financial management.

Why Medical and Adult-Use Revenue May Need Separate Tracking

One of the biggest planning questions is how 280E relief will apply to businesses with mixed activity.

Many cannabis companies operate in both medical and adult-use markets. They may share employees, facilities, inventory systems, administrative expenses, marketing budgets, and management teams. If Schedule III treatment applies only to qualifying medical cannabis activity, operators may need to separate medical revenue and expenses from adult-use revenue and expenses.

Treasury has also indicated that upcoming guidance is expected to address businesses with multiple activities, including how 280E may apply only to activity involving Schedule I or II substances, per its recent announcement.

That could make expense allocation a major issue.

Businesses may need to document:

• Medical versus adult-use sales
• Shared labor costs
• Facility usage
• Inventory movement
• Security costs
• Management expenses
• Marketing and administrative expenses
• Cost allocation methods

This is where accounting discipline becomes critical. If a cannabis company wants to claim deductions tied to qualifying activity, it should be able to support those deductions with clean books, clear documentation, and consistent allocation methods.

Cannabis Tax Planning After Rescheduling

Rescheduling should prompt cannabis operators to revisit their tax planning immediately, especially if they have medical cannabis activity.

This does not mean businesses should rush into aggressive tax positions before final guidance is available. It does mean operators should prepare now so they can respond quickly and responsibly once the rules become clearer.

A good first step is scenario modeling. Operators should work with tax advisors to understand how different outcomes could affect cash flow and taxable income.

Scenarios may include:

• Full 280E relief for qualifying medical activity
• Partial relief based on revenue mix
• Continued 280E exposure for adult-use activity
• Delayed implementation
• Conservative expense allocation
• Changes to estimated tax payments
• State tax differences
• Impact on EBITDA and valuation

Rescheduling could also open the door to tax benefits that many cannabis businesses have not been able to fully use while subject to 280E. That may include more traditional treatment of ordinary business deductions, credits, and planning strategies. At the same time, operators should expect added complexity around documentation, qualifying activity, expense allocation, and timing as federal guidance continues to develop. 

Financial Reporting and Internal Controls Will Become More Important

Cannabis businesses should also use this moment to strengthen financial reporting and internal controls.

If 280E relief becomes available for qualifying activity, operators will need to show how they arrived at their deductions. That means the general ledger, chart of accounts, inventory records, payroll reporting, and expense categories should be organized in a way that supports tax positions.

This is especially important for businesses with both medical and adult-use activity.

Operators should review whether their current accounting systems can clearly show:

• Which revenue is tied to medical sales
• Which expenses are directly tied to qualifying activity
• Which expenses are shared across the business
• How shared expenses are allocated
• Whether inventory records align with sales and compliance reporting
• Whether tax planning assumptions are supported by documentation

Poor records could create risk later, especially if the IRS reviews how deductions were claimed after rescheduling.

What Cannabis Businesses Should Do Now

Cannabis operators do not need to wait for every question to be answered before preparing.

Now is the time to review tax exposure, clean up books, evaluate expense allocation methods, and update financial models. Businesses should also speak with legal counsel about DEA registration and Schedule III compliance requirements.

The DEA registration process has already raised concerns. In another Cannabis Business Times report, industry attorneys questioned language in the registration process and the legal implications for state-licensed operators still navigating an unsettled federal framework.

That creates a need for careful coordination between legal, tax, accounting, and leadership teams.

Cannabis Rescheduling, 280E, and the Bottom Line

Cannabis rescheduling could be a major financial turning point for the industry, especially for medical cannabis businesses that may no longer be subject to 280E on qualifying activity.

But the practical impact will depend on guidance, compliance, documentation, and each company’s revenue mix.

For operators, the best next step is preparation. Clean financials, stronger internal controls, thoughtful tax planning, and clear documentation will put cannabis businesses in a better position as rescheduling guidance continues to develop.

For companies that have spent years operating under the weight of 280E, Schedule III could create meaningful relief. The businesses that are ready to support their tax positions will be in the strongest position to benefit.

CJBS has worked with cannabis businesses on tax, accounting, and financial planning matters since 2016. Our team understands the unique pressures cannabis operators face, from 280E and cash flow planning to entity structure, compliance-driven accounting, and long-term growth decisions. As rescheduling continues to evolve, working with advisors who understand both the tax code and the realities of the cannabis industry can help operators prepare with greater confidence.